Haemonetics Corporation (HAE) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-05-20

Business type: Franchise

How it makes money

It earns through the recurring sale of apheresis disposables and donor management software used by biopharmaceutical firms to collect source plasma for fractionation into pharmaceuticals.

Haemonetics generates profit by supplying the medical hardware and single-use consumables required for apheresis—a process where blood is separated to collect specific components like plasma while returning the rest to the donor. While it serves blood centers and hospitals, its primary earnings engine is the Plasma segment, which provides end-to-end technology for biopharmaceutical companies.

These biopharmaceutical customers pay for automated collection systems to secure 'source plasma,' which is then undergo fractionation—the industrial separation of plasma into proteins used to manufacture treatments for immune and blood disorders. Profitability is driven by the volume of collections, which triggers the sale of proprietary disposables for every donor session.

What protects it: the moat

It maintains its market lead by integrating proprietary donor management software into the supply chains of biopharmaceutical companies that manufacture immune system pharmaceuticals.

The company protects its earnings by embedding its software and hardware directly into the operational workflow of vertically integrated biopharmaceutical giants. These companies, including CSL and Grifols, operate massive networks of collection centers that rely on the company's information technology to manage donor data and supply chain efficiency from the point of donation to fractionation.

This deep integration creates significant switching costs, as transitioning to a rival system would require overhauling the digital and physical infrastructure of entire collection networks. Management's strategy focuses on these high-growth segments where its technology becomes a standard component of the customer's manufacturing process.

What growth costs

It spent $164.4 million to acquire Vivasure Medical and its PerQseal Elite technology while maintaining a $325.0 million remaining authorization for share repurchases.

Growth requires significant capital allocation toward acquisitions and research to expand its Hospital segment. It recently committed $164.4 million to acquire Vivasure Medical, a developer of bioabsorbable vascular closure systems, to capture share in the interventional cardiology market. This acquisition includes contingent consideration based on future sales milestones.

Maintaining the business also involves constant reinvestment in its share repurchase program to manage capital structure. As of March 2026, the company holds $325.0 million in remaining buyback authorization, following $100.0 million in repurchases completed through both 10b5-1 plans and accelerated share repurchase agreements.

What could damage it

The development of FcRn-targeted therapies could provide a therapeutic alternative to plasma-derived pharmaceuticals, structurally reducing the demand for its core source plasma collection disposables.

The company faces a significant structural risk from the emergence of alternative medical treatments. If competitive technologies like FcRn-targeted therapies gain market acceptance, they could replace the plasma-derived pharmaceuticals that currently drive donor demand. Because the company's revenue is heavily concentrated in supplying the collection ecosystem for these drugs, a shift in treatment standards would permanently impair the recurring sales of its disposable components.

This vulnerability is heightened by high customer concentration. If even one of its top biopharmaceutical partners shifts its sourcing strategy or experiences a reduction in fractionation demand, the impact on the company's financial condition would be material and immediate.

About Haemonetics Corporation

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Other companies in Medical Devices